TY  - JOUR
AU  - Sheng, Yingjie
AU  - Beguin, Estelle
AU  - Nesbitt, Heather
AU  - Kamila, Sukanta
AU  - Owen, Joshua
AU  - Barnsley, Lester
AU  - Callan, Bridgeen
AU  - O'Kane, Christopher
AU  - Nomikou, Nikolitsa
AU  - Hamoudi, Rifat
AU  - Taylor, Mark A.
AU  - Love, Mark
AU  - Kelly, Paul
AU  - O'Rourke, Declan
AU  - Stride, Eleanor
AU  - McHale, Anthony P.
AU  - Callan, John F.
TI  - Magnetically responsive microbubbles as delivery vehicles for targeted sonodynamic and antimetabolite therapy of pancreatic cancer
JO  - Journal of controlled release
VL  - 262
SN  - 0168-3659
CY  - New York, NY [u.a.]
PB  - Elsevier
M1  - FZJ-2017-05804
SP  - 192 - 200
PY  - 2017
AB  - Magnetically responsive microbubbles (MagMBs), consisting of an oxygen gas core and a phospholipid coating functionalised with Rose Bengal (RB) and/or 5-fluorouracil (5-FU), were assessed as a delivery vehicle for the targeted treatment of pancreatic cancer using combined antimetabolite and sonodynamic therapy (SDT). MagMBs delivering the combined 5-FU/SDT treatment produced a reduction in cell viability of over 50% when tested against a panel of four pancreatic cancer cell lines in vitro. Intravenous administration of the MagMBs to mice bearing orthotopic human xenograft BxPC-3 tumours yielded a 48.3% reduction in tumour volume relative to an untreated control group (p < 0.05) when the tumour was exposed to both external magnetic and ultrasound fields during administration of the MagMBs. In contrast, application of an external ultrasound field alone resulted in a 27% reduction in tumour volume. In addition, activated caspase and BAX protein levels were both observed to be significantly elevated in tumours harvested from animals treated with the MagMBs in the presence of magnetic and ultrasonic fields when compared to expression of those proteins in tumours from either the control or ultrasound field only groups (p < 0.05). These results suggest MagMBs have considerable potential as a platform to enable the targeted delivery of combined sonodynamic/antimetabolite therapy in pancreatic cancer.
LB  - PUB:(DE-HGF)16
C6  - pmid:28764995
UR  - <Go to ISI:>//WOS:000411201100019
DO  - DOI:10.1016/j.jconrel.2017.07.040
UR  - https://juser.fz-juelich.de/record/836751
ER  -